LENZ Therapeutics(LENZ)
$3.82-0.31 (-7.51%)
LENZ
LENZ Therapeutics financials statements
$3.82
At close:-0.31 (-7.51%)
Want to see LENZ full AI Analyst Report?
LENZ Therapeutics (LENZ) Ratios
427 Followers
LENZ Therapeutics Ratios
LENZ's free cash flow for Q3 2026 was $-22.31M. For the 2026 fiscal year, LENZ's free cash flow was increased by $0.00 and operating cash flow was $-22.31M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.23 | 20.36 | 3.63 | 4.91 | 14.62 |
| Quick Ratio | 14.23 | 20.36 | 3.63 | 4.91 | 14.62 |
| Cash Ratio | 1.19 | 1.94 | 1.90 | 4.68 | 14.61 |
| Solvency Ratio | -3.80 | -4.43 | -0.43 | -0.15 | -2.15 |
| Operating Cash Flow Ratio | -3.26 | -5.71 | -3.26 | -9.26 | -42.18 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 279.88M | $ 200.70M | $ -95.84M | $ -24.48M | $ -14.23M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | -0.00 | -0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | -0.00 | -0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.05 | -0.76 | -1.94 | -1.29 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.06 | 0.04 | 0.03 | 0.00 |
| Net Debt to EBITDA | 0.30 | 0.38 | 0.48 | 4.22 | 0.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 96.31% | 0.00% | 0.00% | 100.00% | 0.00% |
| EBIT Margin | -427.62% | 0.00% | 0.00% | -69.89% | 0.00% |
| EBITDA Margin | -426.12% | 0.00% | 0.00% | -69.83% | 0.00% |
| Operating Profit Margin | -477.46% | 0.00% | 0.00% | -69.89% | 0.00% |
| Pretax Profit Margin | -427.62% | 0.00% | 0.00% | -69.76% | 0.00% |
| Net Profit Margin | -430.25% | 0.00% | 0.00% | -72.07% | 0.00% |
| Continuous Operations Profit Margin | -430.25% | 0.00% | 0.00% | -72.07% | 0.00% |
| Net Income Per EBT | 100.62% | 100.00% | 99.74% | 103.32% | 100.00% |
| EBT Per EBIT | 89.56% | 84.91% | 96.85% | 99.82% | 117.07% |
| Return on Assets (ROA) | -26.85% | -23.12% | -99.42% | -23.03% | -385.93% |
| Return on Equity (ROE) | -28.88% | -24.39% | 75.47% | 44.73% | 497.82% |
| Return on Capital Employed (ROCE) | -32.01% | -28.60% | -139.66% | -27.99% | -353.84% |
| Return on Invested Capital (ROIC) | -31.96% | -28.53% | -138.93% | -27.91% | -353.84% |
| Return on Tangible Assets | -26.85% | -23.12% | -99.42% | -23.03% | -385.93% |
| Earnings Yield | -17.81% | -8.10% | -69.28% | -8.78% | -14.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.86 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.17 | 0.01 | 0.00 | 0.00 | 1.60 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 9.93 | 0.00 | 0.00 | 53.76 | 0.00 |
| Asset Turnover | 0.06 | 0.00 | 0.00 | 0.32 | 0.00 |
| Working Capital Turnover Ratio | 0.08 | 0.00 | 0.00 | 0.55 | 0.00 |
| Cash Conversion Cycle | -2110.94 | -26789.74 | 0.00 | 0.00 | -228.75 |
| Days of Sales Outstanding | 46.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2157.38 | 26789.74 | 0.00 | 0.00 | 228.75 |
| Operating Cycle | 46.45 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.40 | -2.79 | -7.41 | -11.22 | -6.38 |
| Free Cash Flow Per Share | -2.43 | -2.81 | -7.42 | -12.06 | -7.07 |
| Dividend Paid and CapEx Coverage Ratio | -83.64 | -0.19 | -2012.67 | -13.34 | -9.21 |
| Capital Expenditure Coverage Ratio | -83.64 | -126.90 | -2012.67 | -13.34 | -9.21 |
| Operating Cash Flow Coverage Ratio | -84.87 | -43.01 | -183.53 | -351.92 | 0.00 |
| Operating Cash Flow to Sales Ratio | -3.62 | 0.00 | 0.00 | -5.87 | 0.00 |
| Free Cash Flow Yield | -15.18% | -9.74% | -59.81% | -76.79% | -12.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.61 | -12.34 | -1.44 | -11.39 | -6.89 |
| Price-to-Sales (P/S) Ratio | 24.15 | 0.00 | 0.00 | 8.21 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.62 | 3.01 | -1.09 | -5.10 | -34.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.59 | -10.26 | -1.67 | -1.30 | -8.32 |
| Price-to-Operating Cash Flow Ratio | -6.66 | -10.34 | -1.67 | -1.40 | -9.22 |
| Price-to-Earnings Growth (PEG) Ratio | -0.26 | 0.15 | -0.08 | -0.22 | -1.90 |
| Enterprise Value Multiple | -5.37 | -11.98 | -0.91 | -7.54 | -6.70 |
| Enterprise Value | 436.65M | 595.61M | 66.19M | 78.96M | 469.23M |
| EV to EBITDA | -5.37 | -11.98 | -0.91 | -7.54 | -6.70 |
| EV to Sales | 22.88 | 0.00 | 0.00 | 5.26 | 0.00 |
| EV to Free Cash Flow | -6.24 | -9.95 | -1.10 | -0.83 | -8.01 |
| EV to Operating Cash Flow | -6.31 | -10.03 | -1.10 | -0.90 | -8.88 |
| Tangible Book Value Per Share | 9.87 | 9.59 | -11.38 | -3.08 | -1.72 |
| Shareholders’ Equity Per Share | 9.87 | 9.59 | -11.38 | -3.08 | -1.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | 0.00 | -0.03 | 0.00 |
| Revenue Per Share | 0.66 | 0.00 | 0.00 | 1.91 | 0.00 |
| Net Income Per Share | -2.85 | -2.34 | -8.59 | -1.38 | -8.54 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.03 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.97 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.98 | 0.00 | 0.00 | 1.41 | 0.00 |
| SG&A to Revenue | 4.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.66 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.84 | 1.19 | 0.86 | 0.87 | 0.75 |
Currency in USD

